Abstract
AbstractEthanol is metabolized by alcohol dehydrogenase to acetaldehyde and induces cytochrome P450 2E1 (CYP2E1), which generates reactive oxygen species that cause inflammatory liver damage. Clomethiazole, a drug approved for alcohol withdrawal treatment (AWT) in some European countries, inhibits CYP2E1. We hypothesized that clomethiazole would lead to a faster reduction in oxidative stress, inflammatory cytokines, and liver enzymes compared to diazepam treatment. We analysed respective biomarkers in 50 patients undergoing AWT and 25 healthy individuals but found no statistical difference between the two medication groups over 3–5 days. Hence, our hypothesis was not confirmed during this observation period.
Funder
Cheplapharm Arzeimittel
Otto-von-Guericke-Universität Magdeburg
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. World Health Organization (2018) Global status report on alcohol and health 2018. World Health Organization, Geneva
2. Seitz HK, Bataller R, Cortez-Pinto H et al (2018) Alcoholic liver disease. Nat Rev Dis Primer 4:16. https://doi.org/10.1038/s41572-018-0014-7
3. Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie e.V. (DG-SUCHT) (2020) “Screening, Diagnose und Behandlung alkoholbezogener Störungen”
4. Müller UJ, Schuermann F, Dobrowolny H et al (2016) Assessment of pharmacological treatment quality: comparison of symptom-triggered vs. fixed-schedule alcohol withdrawal in clinical practice. Pharmacopsychiatry 49:199–203. https://doi.org/10.1055/s-0042-104508
5. Bahji A, Bach P, Danilewitz M et al (2022) Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis. Addiction 117:2591–2601. https://doi.org/10.1111/add.15853